SEC Form 4 · accession 0001209191-17-032896
ENDRA Life Sciences Inc. · NDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Michael Milos Thornton
Officer — Chief Technology Officer
Period of report
May 12, 2017
Accepted (ET)
May 16, 2017 · 9:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681682
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 12, 2017 | C | 55,020 | $1.40 | A | 59,987 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory NoteF2 | $1.40 | May 12, 2017 | C | — | D | — | May 12, 2017 | Common Stock | — | — | D |
| Stock OptionsF3 | $5.00 | May 12, 2017 | A | 313,338 | A | — | May 12, 2022 | Common Stock | 313,338 | 313,338 | D |
Explanation of responses
- F1These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note, as described in footnote (2).
- F2The principal amount of, and accrued interest on, the Convertible Promissory Note converted into shares of Common Stock of the Issuer at a conversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering.
- F3These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018.